Catalyst Capital Advisors LLC Makes New Investment in Insulet Corporation $PODD

Catalyst Capital Advisors LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 453 shares of the medical instruments supplier’s stock, valued at approximately $142,000.

Other large investors have also recently bought and sold shares of the company. Zions Bancorporation National Association UT purchased a new position in Insulet in the first quarter worth $26,000. Larson Financial Group LLC raised its position in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares in the last quarter. SouthState Corp raised its position in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Kozak & Associates Inc. purchased a new position in Insulet in the second quarter worth $32,000. Finally, Trust Co. of Toledo NA OH purchased a new position in Insulet in the second quarter worth $35,000.

Insulet Trading Down 0.8%

Insulet stock opened at $320.91 on Friday. The stock has a market cap of $22.59 billion, a PE ratio of 97.54, a P/E/G ratio of 2.70 and a beta of 1.40. The stock has a 50-day moving average price of $327.60 and a 200 day moving average price of $304.43. Insulet Corporation has a 52 week low of $226.50 and a 52 week high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Piper Sandler increased their price objective on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Royal Bank Of Canada raised their price target on Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a research report on Friday, October 10th. Jefferies Financial Group restated a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Rothschild & Co Redburn raised their price target on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $352.11.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.